Want to discover the best research that’s occurred this year? Editor, Martha Powell, highlights the best of 2018’s infectious diseases research in an A–Z.
More focus should be put on determining if pathogens are resistant or resilient to antibiotics, according to a new study. This distinction could allow for improved, personalized treatment and help to preserve current antibiotics.
A new trial has begun in the Democratic Republic of Congo, aiming to collect robust data on the safety and efficacy of investigational Ebola therapeutics.
By carefully considering the characteristics of certain old and new antibiotics, it may be possible to overcome many bacterial resistance mechanisms, including when more than one is present.
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.
Collaborative research efforts with scientists from Janssen, the Scripps Research Institute, the University of Hong Kong, the University of Pennsylvania and more has led to success in creating a promising novel long-lasting llama-derived antibody therapy for influenza.
In recent years, researchers have discovered the potential of CRISPR as an antimicrobial. In this blog post we explain the recent advances made in this field and the different approaches by which CRISPR can be used as a new weapon in the battle against antimicrobial resistance.
In this interview, we spoke to Yoav Golan about recent developments in the field of Clostridium difficile infections – from the latest clinical trial results to newly updated guidelines.
Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.